Discovery of molecular determinants of response to targeted therapies in colorectal cancer using patient-derived xenografts (‘xenopatients’)

Ítems similars

• HER2 activating mutations are targets for colorectal cancer treatment
  per: Kavuri, Shyam M., et al.
  Publicat: (2015)
• Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models
  per: Belli, Valentina, et al.
  Publicat: (2019)
• Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
  per: Isella, Claudio, et al.
  Publicat: (2017)
• Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer
  per: Lazzari, Luca, et al.
  Publicat: (2019)
• Implementing Systems Modelling and Molecular Imaging to Predict the Efficacy of BCL-2 Inhibition in Colorectal Cancer Patient-Derived Xenograft Models
  per: O’Farrell, Alice C., et al.
  Publicat: (2020)